Xenija Wagner

Xenija Wagner

Auto-generated profile, based on publicly available information

Xenija Wagner

Department of Psychiatry and Psychotherapy University of Leipzig Leipzig, GermanyDepartment of Psychiatry and Psychotherapy University of Leipzig Leipzig, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2017 in Journal of Medical Internet Research
Verified
Journal Article
Open access
EDEzgi Dogan-Sander
Ezgi Dogan-Sander
CSChristian Sander
Christian Sander
XWXenija Wagner
Xenija Wagner
UHUlrich Hegerl
Ulrich Hegerl
EKElisabeth Kohls
Elisabeth Kohls
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

1 March 2019 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
XWXenija Wagner
Xenija Wagner
MKMichael Kluge
Michael Kluge
To the Editors Clozapine is a second-generation antipsychotic that is known for its high effectiveness in treatment-resistant cases of psychosis not responding to other second-generation antipsychotics or first-generation antipsychotics (FGAs).1 However, because of a number of adverse effects such as cardiotoxicity,2 neutropenia, and binge eating associated with severe weight gain,3 it is not used as first-line treatment. It is recommended only after 2 failed adequate antipsychotic trials.4 Flupentixol is an FGA that is still actively used in various countries including Germany, the United Kingdom, and Sweden.5 It is valued for being as effective as other FGAs5 but less likely to cause extrapyramidal motor side effects.6 We present here a patient with schizophrenia who first received a combination of clozapine and flupentixol. After discontinuation of flupentixol, clozapine plasma concentration abruptly decreased, leading to a severe exacerbation of psychotic symptoms and a suicide attempt. This pattern indicates a strong and clinically relevant pharmacokinetic interaction between these 2 antipsychotics. Mr A. is a 30-year-old man with an 8-year history of schizophrenia. Except for tobacco dependence (25–30 cigarettes per day), he had no psychiatric comorbidities. At admission to the ward, he reported auditory hallucinations, delusions of guilt and reference, and deficits in concentration. He showed severe formal thought disorders, emotional distress, and psychomotor agitation. Because of treatment resistance under various combinations of 4 antipsychotics (quetiapine, amisulpride, olanzapine, flupentixol), the patient agreed to treatment with clozapine. He was receiving a combination of olanzapine, amisulpride, and flupentixol at the time. We first abruptly discontinued olanzapine and tapered out and stopped amisulpride while increasing flupentixol to 12 mg/d. Simultaneously, clozapine (25 mg/d) was started and then stepwise increased to 400 mg/d over a period of 4 weeks. Hypersalivation was treated with pirenzepine (150 mg/d). Blood tests controlling liver function, white blood cell counts, and CK and myoglobin, as well as electrocardiograms controlling QTc time, were performed once weekly. Also, plasma levels of clozapine (therapeutic range, 350–600 μg/L7) and of its active metabolite desmethylclozapine (therapeutic range, 100–300 μg/L) were regularly determined (Fig. 1). At day 30 after starting clozapine (Fig. 1), the patient showed a significant improvement of psychopathology: psychomotor agitation and emotional distress decreased, the formal thought disorders and delusions ceased, and the auditory hallucinations widely disappeared. We then started tapering out the flupentixol over a period of 3 weeks. With flupentixol 2 mg/d (days 48–51) and clozapine 450 mg/d, plasma levels of clozapine (331 μg/L) and desmethylclozapine (212 μg/L) were (almost) in the therapeutic range, and the psychopathological status was still stable. However, 3 days after the complete discontinuation of flupentixol (day 58), the plasma concentrations of clozapine abruptly sank to a subtherapeutic level of 173 μg/L. The number of cigarettes smoked by the patient as well as his caffeine intake had not changed in this period, and medication adherence was monitored by the nursing staff. This decrease of clozapine plasma concentration was associated with a relapse of psychotic symptoms in the form of severe delusions of guilt, auditory hallucinations, psychomotor agitation, and emotional distress. Symptoms had dramatically worsened within only 2 days leading up to the patient attempting suicide by trying to drown himself in a river while wearing a backpack filled with stones. Fortunately, Mr A. could be saved from drowning, and he suffered no injuries and only mild hypothermia. Not being aware of a drug interaction, we assumed a lacking adherence. We therefore continued the medication with 450 mg/d clozapine but monitored medication intake even more precisely.

18 January 2019 in Australian & New Zealand Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
XWXenija Wagner
Xenija Wagner
MKMichael Kluge
Michael Kluge

1 February 2019 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
XWXenija Wagner
Xenija Wagner
MKMichael Kluge
Michael Kluge
Abrupt Decrease of Clozapine Plasma Concentration After Discontinuation of Flupentixol Comedication Xenija Wagner;Michael Kluge; Journal of Clinical Psychopharmacology